Selective oestrogen receptor degraders as treatment for ER positive/HER2 negative advanced/metastatic breast cancer

Bookmark and Share
Published: 19 Dec 2019
Views: 946
Rating:
Save
Dr Philippe Aftimos - Institut Jules Bordet, Brussels, Belgium

Dr Philippe Aftimos speaks to ecancer at the 2019 San Antonio Breast Cancer Symposium about selective oestrogen receptor degraders as treatment for ER positive/HER2 negative advanced/metastatic breast cancer.

He explains that now there is a new more potent class of agents being developed: The selective oestrogen receptor degraders.

These agents are more potent than the therapies that we have because they can overcome the mechanisms of resistance.

Dr Aftimos discusses the background, methods and results of two studies which evaluated the use of oral selective oestrogen receptor degrader elacestrant.